Pfizer (PFE) Other Working Capital Changes (2009 - 2026)

Pfizer (PFE) has 18 years of Other Working Capital Changes data on file, last reported at $1.7 billion in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $1.7 billion, down 9.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.5 billion (down 109.99% YoY), and the FY2025 annual result was -$1.3 billion, up 61.86% from the prior year.
• Other Working Capital Changes climbed to $1.7 billion in Q1 2026 per PFE's latest filing, from -$8.2 billion in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $8.1 billion in Q4 2022 and troughed at -$10.0 billion in Q4 2023.
• A 5-year average of $1.7 billion and a median of $2.8 billion in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2023 and 2025: Other Working Capital Changes jumped 654.38% in 2023, then tumbled 99.4% in 2025.
• A 5-year view of Other Working Capital Changes shows it stood at $8.1 billion in 2022, then sank by 223.24% to -$10.0 billion in 2023, then soared by 160.17% to $6.0 billion in 2024, then sank by 237.4% to -$8.2 billion in 2025, then jumped by 121.04% to $1.7 billion in 2026.
• Business Quant data shows PFE's Other Working Capital Changes at $1.7 billion in Q1 2026, -$8.2 billion in Q4 2025, and $36.0 million in Q3 2025.